Featured News

A recent study evaluated the prevalence of detectable gluten immunogenic peptides (GIPs), which are resistant to digestion and are excreted through the stool and urine, to gauge accidental gluten exposure and adherence to a gluten-free diet in children with celiac disease in the United States.   

Celiac disease world expert Alessio Fasano, MD, recently wrote a commentary on a study that set out to identify a link between inflammatory bowel disease and celiac disease/celiac autoimmunity in children and adults.   

Anokion SA released successful results from their Phase 1 ACeD clinical trial and they will be moving forward with Phase 2 trials later this year.

The Celiac Disease Foundation is in discussion with a team at the University of Colorado, Denver to develop the first-ever, FDA-approved pediatric PRO (patient-reported outcome tool).

A recent study found that avoidant/restrictive food intake disorder (ARFID) is common among people with celiac disease.

On April 8 and April 9, the Celiac Disease Foundation is sponsoring the Columbia University Celiac Disease Center International Symposium on Celiac Disease.

Researchers found that children initially diagnosed with potential celiac disease had a high risk of developing celiac disease.

Anokion SA announced successful completion of its Phase 1 clinical trial evaluating KAN-101 for the treatment of celiac disease, with promising results.

researchers concluded that patients with celiac disease who are infected with COVID-19 are not at higher risk of hospitalization.

I am pleased to share a research grant awarded to the Dubcovsky Lab at UC Davis for Development of a Novel Dietary Treatment for Celiac Disease that may significantly reduce the suffering experienced by our patient community.